Table 2.
MSC-derived EVs for cancer therapy.
| Target Therapy | MSC Origin | Cargo Type | Cargo | Outcome | Reference |
|---|---|---|---|---|---|
| Breast cancer | Bone marrow | miRNA | miR-100 | Suppressed angiogenesis | [121] |
| Bone marrow | miR-23b | Promoted dormancy | [122] | ||
| Bone marrow | miR-16 | Suppressed angiogenesis | [123] | ||
| Glioma | Bone marrow | miR-124/miR-145 | Decreased migration and self-renewal | [124] | |
| Bone marrow | miR-146b | Inhibited tumor growth | [125] | ||
| Bone marrow | miR-124a | Reduced viability | [121] | ||
| Bone marrow | miR-133b | Inhibited proliferation, invasion, and migration | [126] | ||
| Osteosarcoma | Bone marrow | miR-143 | Suppressed migration | [127] | |
| Hepatocellular carcinoma | Adipose | miR-122 | Growth inhibition | [128] | |
| Prostate cancer | Adipose | miR-145 | Suppressed cancer progression | [129] | |
| Multiple myeloma | Bone marrow | miR-15a | Growth inhibition | [130] | |
| Pancreatic cancer | Bone marrow | miR-1231 | Inhibited cancer activity | [131] | |
| Bone marrow | siRNA | siKrasG12D-1 | Induced apoptosis | [132] | |
| Hepatocellular carcinoma | Bone marrow | siGRP78 | Growth inhibition | [133] |